{"entity": "journal", "iuid": "789bc7583a9248a6bf62c0f521085907", "timestamp": "2026-09-26T23:27:29.049Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Biol%20Blood%20Marrow%20Transplant.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Biol%20Blood%20Marrow%20Transplant"}}, "title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "issn-l": null, "publications_count": 21, "publications": [{"entity": "publication", "iuid": "35d5ef2b1962421485b6447202bbcca6", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/35d5ef2b1962421485b6447202bbcca6.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/35d5ef2b1962421485b6447202bbcca6"}}, "title": "Histopathological Grading of Oral Mucosal Chronic Graft-versus-Host Disease: Large Cohort Analysis.", "authors": [{"family": "Tollemar", "given": "Victor", "initials": "V"}, {"family": "Tudzarovski", "given": "Nikcole", "initials": "N"}, {"family": "Warfvinge", "given": "Gunnar", "initials": "G"}, {"family": "Yarom", "given": "Naom", "initials": "N"}, {"family": "Remberger", "given": "Mats", "initials": "M"}, {"family": "Heymann", "given": "Robert", "initials": "R"}, {"family": "Garming Legert", "given": "Karin", "initials": "K"}, {"family": "Sugars", "given": "Rachael V", "initials": "RV"}], "type": "journal article", "published": "2020-10-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "26", "issue": "10", "pages": "1971-1979", "issn-l": null}, "abstract": "Graft-versus-host disease (GVHD) can manifest as acute or chronic complications in patients after hematopoietic cell transplantation (HCT). Oral chronic GVHD (cGVHD) occurs in approximately 70% of HCT recipients and includes lichenoid-like mucosal reactions, restricted mouth opening, and salivary gland dysfunction. However, the underlying histopathological presentation remains to be validated in large cohorts. We characterized the histopathological features of oral mucosal cGVHD and devised a scoring model in a large patient cohort (n = 112). Oral mucosal biopsy sections (n = 303) with and without oral cGVHD were identified from archived and current HCT recipients with additional healthy controls. Histological screening was performed on hematoxylin and eosin-stained and periodic acid-Schiff-stained sections. A points-based grading tool (0 to 19, grade 0 to IV) was established based on intraepithelial lymphocytes and band-like inflammatory infiltrate, atrophic epithelium with basal cell liquefaction degeneration, including apoptosis, as well as separation of epithelium and pseudo-rete ridges. Validation involved 62 biopsy specimens, including post-HCT (n = 47) and healthy (n = 15) specimens. Remaining biopsy specimens (n = 199) were blindly graded by 3 observers. Histological severity was correlated with clinical diagnostic and distinctive features, demonstrating a spectrum of individual patient severity, including frequent signs of subclinical GVHD in healthy mucosa. However, oral cGVHD presented with significantly higher (P < .001) scores compared with HCT controls, with moderate to high positive likelihood ratios for inflammatory infiltrate, exocytosis, and basal membrane alterations. The grade II-IV biopsy specimens demonstrated a histopathological diagnosis of active mucosal lichenoid-like cGVHD, highlighting the importance of correlating clinical presentation with the dynamic histopathological processes for improved patient stratification. In addition, this tool could be used for assessing treatments, pathological processes, and immune cellular content to provide further insight into this debilitating disease.", "doi": "10.1016/j.bbmt.2020.06.031", "pmid": "32659433", "labels": [], "xrefs": [{"db": "pii", "key": "S1083-8791(20)30401-8"}], "notes": [], "created": "2026-09-23T11:58:19.319Z", "modified": "2026-09-23T11:58:19.353Z"}, {"entity": "publication", "iuid": "47215647d9764c2ab14c63291a5decfd", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/47215647d9764c2ab14c63291a5decfd.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/47215647d9764c2ab14c63291a5decfd"}}, "title": "The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.", "authors": [{"family": "Arnold", "given": "Staci D", "initials": "SD"}, {"family": "Brazauskas", "given": "Ruta", "initials": "R"}, {"family": "He", "given": "Naya", "initials": "N"}, {"family": "Li", "given": "Yimei", "initials": "Y"}, {"family": "Hall", "given": "Matt", "initials": "M"}, {"family": "Atsuta", "given": "Yoshiko", "initials": "Y"}, {"family": "Dalal", "given": "Jignesh", "initials": "J"}, {"family": "Hahn", "given": "Theresa", "initials": "T"}, {"family": "Khera", "given": "Nandita", "initials": "N"}, {"family": "Bonfim", "given": "Carmem", "initials": "C"}, {"family": "Hashmi", "given": "Shahrukh", "initials": "S"}, {"family": "Parsons", "given": "Susan", "initials": "S"}, {"family": "Wood", "given": "William A", "initials": "WA"}, {"family": "Steinberg", "given": "Amir", "initials": "A"}, {"family": "Freytes", "given": "C\u00e9sar O", "initials": "CO"}, {"family": "Dandoy", "given": "Christopher E", "initials": "CE"}, {"family": "Marks", "given": "David I", "initials": "DI"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Bitan", "given": "Menachem", "initials": "M"}, {"family": "Diaz", "given": "Miguel Angel", "initials": "MA"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "Seber", "given": "Adriana", "initials": "A"}, {"family": "Wirk", "given": "Baldeep", "initials": "B"}, {"family": "LeMaistre", "given": "C Fred", "initials": "CF"}, {"family": "Ustun", "given": "Celalettin", "initials": "C"}, {"family": "Duncan", "given": "Christine", "initials": "C"}, {"family": "Rizzieri", "given": "David", "initials": "D"}, {"family": "Szwajcer", "given": "David", "initials": "D"}, {"family": "Fagioli", "given": "Franca", "initials": "F"}, {"family": "Frangoul", "given": "Haydar", "initials": "H"}, {"family": "Knight", "given": "Jennifer M", "initials": "JM"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Mehta", "given": "Paulette", "initials": "P"}, {"family": "Schears", "given": "Raquel", "initials": "R"}, {"family": "Satwani", "given": "Prakash", "initials": "P"}, {"family": "Pulsipher", "given": "Michael A", "initials": "MA"}, {"family": "Aplenc", "given": "Richard", "initials": "R"}, {"family": "Saber", "given": "Wael", "initials": "W"}], "type": "journal article", "published": "2020-09-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "26", "issue": "9", "pages": "1747-1756", "issn-l": null}, "abstract": "Allogeneic hematopoietic stem cell transplantation (alloHCT) may be associated with significant morbidity and mortality, resulting in increased healthcare utilization (HCU). To date, no multicenter comparative cost analyses have specifically evaluated alloHCT in children with acute leukemia. In this retrospective cohort study, we examined the relationship between survival and HCU while investigating the hypothesis that matched sibling donor (MSD) alloHCT has significantly lower inpatient HCU with unrelated donor (URD) alloHCT, and that among URDs, umbilical cord blood (UCB) alloHCT will have higher initial utilization but lower long-term utilization. Clinical and transplantation outcomes data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were merged with inpatient cost data from the Pediatric Health Information System (PHIS) database using a probabilistic merge methodology. The merged dataset comprised US patients age 1 to 21 years who underwent alloHCT for acute leukemia between 2004 and 2011 with comprehensive CIBMTR data at a PHIS hospital. AlloHCT was analyzed by donor type, with specific analysis of utilization and costs using PHIS claims data. The primary outcomes of overall survival (OS), leukemia-free survival (LFS), and inpatient costs were evaluated using Kaplan-Meier curves and Cox and Poisson models. A total of 632 patients were identified in both the CIBMTR and PHIS data. The 5-year LFS was 60% for MSD alloHCT, 47% for well-matched matched unrelated donor bone marrow (MUD) alloHCT, 48% for mismatched unrelated donor alloHCT, and 45% for UCB alloHCT (P = .09). Total adjusted costs were significantly lower for MSD alloHCT versus MUD alloHCT by day 100 (adjusted cost ratio [ACR], .73; 95% confidence interval [CI], .62 to .86; P < .001), and higher for UCB alloHCT versus MUD alloHCT (ACR, 1.27; 95% CI, 1.11 to 1.45; P < .001). By 2 years, total adjusted costs remained significantly lower for MSD alloHCT compared with MUD alloHCT (ACR, .67; 95% CI, .56 to .81; P < .001) and higher for UCB alloHCT compared with MUD alloHCT (ACR, 1.25; 95% CI, 1.02 to 1.52; P = .0280). Our data show that UCB and MUD alloHCT provide similar survival outcomes; however, MUD alloHCT has a significant advantage in cost by day 100 and 2 years. More research is needed to determine whether the cost difference among URD alloHCT approaches remains significant with a larger sample size and/or beyond 2 years post-alloHCT.", "doi": "10.1016/j.bbmt.2020.05.016", "pmid": "32464284", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1610201"}, {"db": "pmc", "key": "PMC7518194"}, {"db": "pii", "key": "S1083-8791(20)30314-1"}], "notes": [], "created": "2026-09-23T13:03:37.490Z", "modified": "2026-09-23T13:03:37.516Z"}, {"entity": "publication", "iuid": "c927488d9a3043df886ee94bbe03cd7f", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c927488d9a3043df886ee94bbe03cd7f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c927488d9a3043df886ee94bbe03cd7f"}}, "title": "Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.", "authors": [{"family": "Im", "given": "Annie", "initials": "A"}, {"family": "Rashidi", "given": "Armin", "initials": "A"}, {"family": "Wang", "given": "Tao", "initials": "T"}, {"family": "Hemmer", "given": "Michael", "initials": "M"}, {"family": "MacMillan", "given": "Margaret L", "initials": "ML"}, {"family": "Pidala", "given": "Joseph", "initials": "J"}, {"family": "Jagasia", "given": "Madan", "initials": "M"}, {"family": "Pavletic", "given": "Steven", "initials": "S"}, {"family": "Majhail", "given": "Navneet S", "initials": "NS"}, {"family": "Weisdorf", "given": "Daniel", "initials": "D"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Agrawal", "given": "Vaibhav", "initials": "V"}, {"family": "Al-Homsi", "given": "A Samer", "initials": "AS"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Askar", "given": "Medhat", "initials": "M"}, {"family": "Auletta", "given": "Jeffery J", "initials": "JJ"}, {"family": "Bashey", "given": "Asad", "initials": "A"}, {"family": "Beitinjaneh", "given": "Amer", "initials": "A"}, {"family": "Bhatt", "given": "Vijaya Raj", "initials": "VR"}, {"family": "Byrne", "given": "Michael", "initials": "M"}, {"family": "Cahn", "given": "Jean-Yves", "initials": "JY"}, {"family": "Cairo", "given": "Mitchell", "initials": "M"}, {"family": "Castillo", "given": "Paul", "initials": "P"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "Chhabra", "given": "Saurabh", "initials": "S"}, {"family": "Choe", "given": "Hannah", "initials": "H"}, {"family": "Ciurea", "given": "Stefan", "initials": "S"}, {"family": "Daly", "given": "Andrew", "initials": "A"}, {"family": "Perez", "given": "Miguel Angel Diaz", "initials": "MAD"}, {"family": "Farhadfar", "given": "Nosha", "initials": "N"}, {"family": "Gadalla", "given": "Shahinaz M", "initials": "SM"}, {"family": "Gale", "given": "Robert", "initials": "R"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "Hanna", "given": "Rabi", "initials": "R"}, {"family": "Hematti", "given": "Peiman", "initials": "P"}, {"family": "Herzig", "given": "Roger", "initials": "R"}, {"family": "Hildebrandt", "given": "Gerhard C", "initials": "GC"}, {"family": "Lad", "given": "Deepesh P", "initials": "DP"}, {"family": "Lee", "given": "Catherine", "initials": "C"}, {"family": "Lehmann", "given": "Leslie", "initials": "L"}, {"family": "Lekakis", "given": "Lazaros", "initials": "L"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kharfan-Dabaja", "given": "Mohamed A", "initials": "MA"}, {"family": "Khandelwal", "given": "Pooja", "initials": "P"}, {"family": "Martino", "given": "Rodrigo", "initials": "R"}, {"family": "Murthy", "given": "Hemant S", "initials": "HS"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "O'Brien", "given": "Tracey A", "initials": "TA"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Patel", "given": "Sagar S", "initials": "SS"}, {"family": "Perales", "given": "Miguel-Angel", "initials": "MA"}, {"family": "Prestidge", "given": "Tim", "initials": "T"}, {"family": "Qayed", "given": "Muna", "initials": "M"}, {"family": "Romee", "given": "Rizwan", "initials": "R"}, {"family": "Schoemans", "given": "H\u00e9l\u00e8ne", "initials": "H"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Sharma", "given": "Akshay", "initials": "A"}, {"family": "Solh", "given": "Melhem", "initials": "M"}, {"family": "Strair", "given": "Roger", "initials": "R"}, {"family": "Teshima", "given": "Takanori", "initials": "T"}, {"family": "Urbano-Ispizua", "given": "Alvaro", "initials": "A"}, {"family": "Van der Poel", "given": "Marjolein", "initials": "M"}, {"family": "Vij", "given": "Ravi", "initials": "R"}, {"family": "Wagner", "given": "John L", "initials": "JL"}, {"family": "William", "given": "Basem", "initials": "B"}, {"family": "Wirk", "given": "Baldeep", "initials": "B"}, {"family": "Yared", "given": "Jean A", "initials": "JA"}, {"family": "Spellman", "given": "Steve R", "initials": "SR"}, {"family": "Arora", "given": "Mukta", "initials": "M"}, {"family": "Hamilton", "given": "Betty K", "initials": "BK"}], "type": "journal article", "published": "2020-08-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "26", "issue": "8", "pages": "1459-1468", "issn-l": null}, "abstract": "Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus <29 years) was significantly associated with higher rates of grade 2 to 4 acute GVHD (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.11 to 2.12; P = .01). In contrast, PB compared to BM as a stem cell source was a significant risk factor for the development of chronic GVHD (HR, 1.70; 95% CI, 1.11 to 2.62; P = .01) in the RIC setting. There were no differences in relapse or overall survival between groups. Donor age and graft source are risk factors for acute and chronic GVHD, respectively, after PTCy-based haplo-HCT. Our results indicate that in RIC haplo-HCT, the risk of chronic GVHD is higher with PB stem cells, without any difference in relapse or overall survival.", "doi": "10.1016/j.bbmt.2020.05.001", "pmid": "32434056", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1604025"}, {"db": "pmc", "key": "PMC7391266"}, {"db": "pii", "key": "S1083-8791(20)30286-X"}], "notes": [], "created": "2026-09-23T08:37:47.944Z", "modified": "2026-09-23T08:37:47.996Z"}, {"entity": "publication", "iuid": "cea2db578d16484a90971f0d262cfc0b", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/cea2db578d16484a90971f0d262cfc0b.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/cea2db578d16484a90971f0d262cfc0b"}}, "title": "Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors.", "authors": [{"family": "Hsu", "given": "Jack W", "initials": "JW"}, {"family": "Shaw", "given": "Bronwen E", "initials": "BE"}, {"family": "Kim", "given": "Soyoung", "initials": "S"}, {"family": "Logan", "given": "Brent R", "initials": "BR"}, {"family": "Sees", "given": "Jennifer A", "initials": "JA"}, {"family": "Confer", "given": "Dennis L", "initials": "DL"}, {"family": "Pulsipher", "given": "Michael A", "initials": "MA"}, {"family": "Shah", "given": "Nirali", "initials": "N"}, {"family": "Switzer", "given": "Galen E", "initials": "GE"}, {"family": "Abidi", "given": "Muneer H", "initials": "MH"}, {"family": "Ahmed", "given": "Ibrahim A", "initials": "IA"}, {"family": "Anderlini", "given": "Paulo N", "initials": "PN"}, {"family": "Bredeson", "given": "Christopher", "initials": "C"}, {"family": "Chhabra", "given": "Saurabh", "initials": "S"}, {"family": "Dandoy", "given": "Christopher E", "initials": "CE"}, {"family": "Diaz", "given": "Miguel Angel", "initials": "MA"}, {"family": "Farhadfar", "given": "Nosha", "initials": "N"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "Hale", "given": "Gregory A", "initials": "GA"}, {"family": "Hematti", "given": "Peiman", "initials": "P"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kasow", "given": "Kimberly A", "initials": "KA"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Liesveld", "given": "Jane L", "initials": "JL"}, {"family": "Murthy", "given": "Hemant S", "initials": "HS"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Schears", "given": "Raquel", "initials": "R"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Solh", "given": "Melhern", "initials": "M"}, {"family": "Spitzer", "given": "Thomas", "initials": "T"}, {"family": "Steinberg", "given": "Amir", "initials": "A"}, {"family": "Sugrue", "given": "Michele", "initials": "M"}, {"family": "Warkentin", "given": "Phyllis", "initials": "P"}, {"family": "Wingard", "given": "John R", "initials": "JR"}], "type": "journal article", "published": "2020-06-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "26", "issue": "6", "pages": "1210-1217", "issn-l": null}, "abstract": "Peripheral blood stem cells (PBSCs) have been increasingly used for allogeneic hematopoietic cell transplantation instead of bone marrow stem cells. Current National Marrow Donor Program policy recommends 5 days of daily filgrastim, followed by either 1 or 2 days of apheresis for unrelated donors, depending on collection center choice. To date, there are no published studies comparing the differences in donor experience between 1 day and 2 days of apheresis. We examined 22,348 adult unrelated donor collections in 184 centers between 2006 and 2016. Of these 22,348 donors, 20,004 (89.5%) had collection on 1 day, and the other 2344 (9.5%) had collection over 2 days. Information on why donors underwent apheresis in 1 day or 2 days was not available. Donors who underwent apheresis in 1 day were more likely to be male (67% versus 46%; P < .001), younger (age <30 years, 48% versus 36%; P < .001), and have a higher body weight (83.0 kg versus 75.9 kg; P< .001) and body mass index (BMI; >30, 30% versus 22%; P < .001). Successful collection of the requested CD34+ cell count was achieved on the first day in 82% of 1-day collections and in 16% of 2-day collections. Despite not administering filgrastim the evening after the first day of collection in patients who underwent 2 days of apheresis, the median concentration of CD34+ cells/L in the product was higher on the second day of apheresis compared with the first day (23.8 \u00d7 106 CD34+/L on day 1 versus 28.7 \u00d7 106 CD34+/L on day 2; P< .001). Donors who underwent collection in 1 day were less likely to experience citrate toxicity (36% versus 52%; P< .001), hospitalization (1% versus 6%; P< .001), and other side effects related to apheresis (Modified Toxicity Criteria incidence: 20% versus 26%; P < .001). Female sex, older age, collection via central lines, and higher BMI were factors associated with greater likelihood for the development of toxicity, whereas less toxicity was noted in those with higher CD34+ counts and more blood processed on the first day of collection. We conclude that although unrelated donors can be successfully collected in 1 day or 2 days, 1-day apheresis procedures were associated with less overall toxicity, and thus we recommend single-day collections, especially if the requested number of cells have been collected in 1 day.", "doi": "10.1016/j.bbmt.2020.02.011", "pmid": "32088366", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1589932"}, {"db": "pmc", "key": "PMC7347029"}, {"db": "pii", "key": "S1083-8791(20)30096-3"}], "notes": [], "created": "2026-09-23T12:10:48.059Z", "modified": "2026-09-23T12:10:48.092Z"}, {"entity": "publication", "iuid": "f70d5c53ecdf4178a6465d25cbf3863f", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/f70d5c53ecdf4178a6465d25cbf3863f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/f70d5c53ecdf4178a6465d25cbf3863f"}}, "title": "The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.", "authors": [{"family": "Schmidt", "given": "Sarah", "initials": "S"}, {"family": "Liu", "given": "Ying", "initials": "Y"}, {"family": "Hu", "given": "Zhen-Huan", "initials": "ZH"}, {"family": "Williams", "given": "Kirsten M", "initials": "KM"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Vij", "given": "Ravi", "initials": "R"}, {"family": "Kharfan-Dabaja", "given": "Mohamed A", "initials": "MA"}, {"family": "Ort\u00ed", "given": "Guillermo", "initials": "G"}, {"family": "Wiernik", "given": "Peter H", "initials": "PH"}, {"family": "Weisdorf", "given": "Daniel", "initials": "D"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Herzig", "given": "Roger", "initials": "R"}, {"family": "Wirk", "given": "Baldeep", "initials": "B"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "Bacher", "given": "Ulrike", "initials": "U"}, {"family": "Chaudhri", "given": "Naeem A", "initials": "NA"}, {"family": "Nathan", "given": "Sunita", "initials": "S"}, {"family": "Farhadfar", "given": "Nosha", "initials": "N"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "Szer", "given": "Jeffrey", "initials": "J"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Hsu", "given": "Jack W", "initials": "JW"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Maharaj", "given": "Dipnarine", "initials": "D"}, {"family": "George", "given": "Biju", "initials": "B"}, {"family": "Hildebrandt", "given": "Gerhard C", "initials": "GC"}, {"family": "Agrawal", "given": "Vaibhav", "initials": "V"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Alyea", "given": "Edwin", "initials": "E"}, {"family": "Popat", "given": "Uday", "initials": "U"}, {"family": "Sobecks", "given": "Ronald", "initials": "R"}, {"family": "Scott", "given": "Bart L", "initials": "BL"}, {"family": "Holter Chakrabarty", "given": "Jennifer", "initials": "J"}, {"family": "Saber", "given": "Wael", "initials": "W"}], "type": "journal article", "published": "2020-06-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "26", "issue": "6", "pages": "1137-1143", "issn-l": null}, "abstract": "Treatment for relapse of chronic myeloid leukemia (CML) following hematopoietic cell transplantation (HCT) includes tyrosine kinase inhibitors (TKIs) with or without donor lymphocyte infusions (DLIs), but the most effective treatment strategy is unknown. This study was performed through the Center for International Blood and Marrow Transplant Research (CIBMTR) database. We retrospectively reviewed all patients reported to the CIBMTR registry from 2002 to 2014 who underwent HCT for CML and were alive 30 days postrelapse. A total of 215 HCT recipients relapsed and were analyzed in the following groups: (1) TKI alone (n = 128), (2) TKI with DLI (n = 48), and (3) DLI without TKI (n = 39). In multivariate analysis, disease status prior to HCT had a significant effect on overall survival (OS). Patients who received a DLI alone compared with a TKI with a DLI had inferior survival (hazard ratio, 2.28; 95% confidence interval, 1.23 to 4.24; P= .009). Those who received a TKI alone had similar survival compared with those who received a TKI with a DLI (P = .81). These data support that despite use of TKIs pretransplantation, TKI salvage therapy continues to provide significant survival following relapse in patients with CML following HCT. These data do not suggest that adding a DLI to a TKI adds an improvement in OS.", "doi": "10.1016/j.bbmt.2020.02.006", "pmid": "32062061", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1589931"}, {"db": "pmc", "key": "PMC7367282"}, {"db": "pii", "key": "S1083-8791(20)30090-2"}], "notes": [], "created": "2026-09-23T10:13:55.358Z", "modified": "2026-09-23T10:52:19.688Z"}, {"entity": "publication", "iuid": "b39ee73323bc4fd8b4aef2b5627b5e9a", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/b39ee73323bc4fd8b4aef2b5627b5e9a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/b39ee73323bc4fd8b4aef2b5627b5e9a"}}, "title": "Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.", "authors": [{"family": "DeFilipp", "given": "Zachariah", "initials": "Z"}, {"family": "Ancheta", "given": "Richard", "initials": "R"}, {"family": "Liu", "given": "Ying", "initials": "Y"}, {"family": "Hu", "given": "Zhen-Huan", "initials": "ZH"}, {"family": "Gale", "given": "Robert Peter", "initials": "RP"}, {"family": "Snyder", "given": "David", "initials": "D"}, {"family": "Schouten", "given": "Harry C", "initials": "HC"}, {"family": "Kalaycio", "given": "Matt", "initials": "M"}, {"family": "Hildebrandt", "given": "Gerhard C", "initials": "GC"}, {"family": "Ustun", "given": "Celalettin", "initials": "C"}, {"family": "Daly", "given": "Andrew", "initials": "A"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Inamoto", "given": "Yoshihiro", "initials": "Y"}, {"family": "Litzow", "given": "Mark", "initials": "M"}, {"family": "Szer", "given": "Jeffrey", "initials": "J"}, {"family": "Savoie", "given": "Mary Lynn", "initials": "ML"}, {"family": "Hossain", "given": "Nasheed", "initials": "N"}, {"family": "Kharfan-Dabaja", "given": "Mohamed A", "initials": "MA"}, {"family": "Hamadani", "given": "Mehdi", "initials": "M"}, {"family": "Reshef", "given": "Ran", "initials": "R"}, {"family": "Bajel", "given": "Ashish", "initials": "A"}, {"family": "Schultz", "given": "Kirk R", "initials": "KR"}, {"family": "Gadalla", "given": "Shahinaz", "initials": "S"}, {"family": "Gerds", "given": "Aaron", "initials": "A"}, {"family": "Liesveld", "given": "Jane", "initials": "J"}, {"family": "Juckett", "given": "Mark B", "initials": "MB"}, {"family": "Kamble", "given": "Rammurti", "initials": "R"}, {"family": "Hashmi", "given": "Shahrukh", "initials": "S"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Solh", "given": "Melhem", "initials": "M"}, {"family": "Bacher", "given": "Ulrike", "initials": "U"}, {"family": "Lazarus", "given": "Hillard", "initials": "H"}, {"family": "Olsson", "given": "Richard", "initials": "R"}, {"family": "Cahn", "given": "Jean-Yves", "initials": "JY"}, {"family": "Grunwald", "given": "Michael R", "initials": "MR"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Yared", "given": "Jean", "initials": "J"}, {"family": "Rowe", "given": "Jacob M", "initials": "JM"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "Chaudhri", "given": "Naeem A", "initials": "NA"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Beitinjaneh", "given": "Amer", "initials": "A"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Hsu", "given": "Jack W", "initials": "JW"}, {"family": "Ramanathan", "given": "Muthalagu", "initials": "M"}, {"family": "Alyea", "given": "Edwin", "initials": "E"}, {"family": "Popat", "given": "Uday", "initials": "U"}, {"family": "Sobecks", "given": "Ronald", "initials": "R"}, {"family": "Saber", "given": "Wael", "initials": "W"}], "type": "journal article", "published": "2020-03-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "26", "issue": "3", "pages": "472-479", "issn-l": null}, "abstract": "It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML who underwent transplantation between 2007 and 2014 and received maintenance TKI following HCT (n = 89) compared with no TKI maintenance (n = 301), as reported to the Center for International Blood and Marrow Transplant Research. All patients received TKI therapy before HCT. The majority of patients had a disease status of first chronic phase at HCT (n = 240; 62%). The study was conducted as a landmark analysis, excluding patients who died, relapsed, had chronic graft-versus-host disease, or were censored before day +100 following HCT. Of the 89 patients who received TKI maintenance, 77 (87%) received a single TKI and the other 12 (13%) received multiple sequential TKIs. The most common TKIs used for maintenance were dasatinib (n = 50), imatinib (n = 27), and nilotinib (n = 27). As measured from day +100, the adjusted estimates for 5-year relapse (maintenance, 35% versus no maintenance, 26%; P = .11), leukemia-free survival (maintenance, 42% versus no maintenance, 44%; P = .65), or overall survival (maintenance, 61% versus no maintenance, 57%; P = .61) did not differ significantly between patients receiving TKI maintenance or no maintenance. These results remained unchanged in multivariate analysis and were not modified by disease status before transplantation. In conclusion, our data from this day +100 landmark analysis do not demonstrate a significant impact of maintenance TKI therapy on clinical outcomes. The optimal approach to TKI administration in the post-transplantation setting in patients with CML remains undetermined.", "doi": "10.1016/j.bbmt.2019.10.017", "pmid": "31669399", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1550147"}, {"db": "pmc", "key": "PMC7358778"}, {"db": "pii", "key": "S1083-8791(19)30674-3"}], "notes": [], "created": "2026-09-23T09:53:45.032Z", "modified": "2026-09-23T10:27:51.119Z"}, {"entity": "publication", "iuid": "ce07dafa94264153bbd2381895060f14", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/ce07dafa94264153bbd2381895060f14.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/ce07dafa94264153bbd2381895060f14"}}, "title": "Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.", "authors": [{"family": "Buchbinder", "given": "David", "initials": "D"}, {"family": "Brazauskas", "given": "Ruta", "initials": "R"}, {"family": "Bo-Subait", "given": "Khalid", "initials": "K"}, {"family": "Ballen", "given": "Karen", "initials": "K"}, {"family": "Parsons", "given": "Susan", "initials": "S"}, {"family": "John", "given": "Tami", "initials": "T"}, {"family": "Hahn", "given": "Theresa", "initials": "T"}, {"family": "Sharma", "given": "Akshay", "initials": "A"}, {"family": "Steinberg", "given": "Amir", "initials": "A"}, {"family": "D'Souza", "given": "Anita", "initials": "A"}, {"family": "Kumar", "given": "Anita J", "initials": "AJ"}, {"family": "Yoshimi", "given": "Ayami", "initials": "A"}, {"family": "Wirk", "given": "Baldeep", "initials": "B"}, {"family": "Shaw", "given": "Bronwen", "initials": "B"}, {"family": "Freytes", "given": "C\u00e9sar", "initials": "C"}, {"family": "LeMaistre", "given": "Charles", "initials": "C"}, {"family": "Bredeson", "given": "Christopher", "initials": "C"}, {"family": "Dandoy", "given": "Christopher", "initials": "C"}, {"family": "Almaguer", "given": "David", "initials": "D"}, {"family": "Marks", "given": "David I", "initials": "DI"}, {"family": "Szwajcer", "given": "David", "initials": "D"}, {"family": "Hale", "given": "Gregory", "initials": "G"}, {"family": "Schouten", "given": "Harry", "initials": "H"}, {"family": "Hashem", "given": "Hasan", "initials": "H"}, {"family": "Schoemans", "given": "H\u00e9l\u00e8ne", "initials": "H"}, {"family": "Murthy", "given": "Hemant S", "initials": "HS"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "Tay", "given": "Jason", "initials": "J"}, {"family": "Yared", "given": "Jean A", "initials": "JA"}, {"family": "Adekola", "given": "Kehinde", "initials": "K"}, {"family": "Schultz", "given": "Kirk R", "initials": "KR"}, {"family": "Lehmann", "given": "Leslie", "initials": "L"}, {"family": "Burns", "given": "Linda", "initials": "L"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Diaz", "given": "Miguel Angel", "initials": "MA"}, {"family": "Majhail", "given": "Navneet", "initials": "N"}, {"family": "Farhadfar", "given": "Nosha", "initials": "N"}, {"family": "Kamble", "given": "Rammurti", "initials": "R"}, {"family": "Olsson", "given": "Richard", "initials": "R"}, {"family": "Schears", "given": "Raquel", "initials": "R"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Beattie", "given": "Sara", "initials": "S"}, {"family": "Chhabra", "given": "Saurabh", "initials": "S"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Badawy", "given": "Sherif", "initials": "S"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Ciurea", "given": "Stefan", "initials": "S"}, {"family": "Marino", "given": "Susana", "initials": "S"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "Kuwatsuka", "given": "Yachiyo", "initials": "Y"}, {"family": "Inamoto", "given": "Yoshihiro", "initials": "Y"}, {"family": "Khera", "given": "Nandita", "initials": "N"}, {"family": "Hashmi", "given": "Shahrukh", "initials": "S"}, {"family": "Wood", "given": "William", "initials": "W"}, {"family": "Saber", "given": "Wael", "initials": "W"}], "type": "journal article", "published": "2020-03-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "26", "issue": "3", "pages": "553-561", "issn-l": null}, "abstract": "Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.", "doi": "10.1016/j.bbmt.2019.11.003", "pmid": "31726205", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1600729"}, {"db": "pmc", "key": "PMC7367505"}, {"db": "pii", "key": "S1083-8791(19)30743-8"}], "notes": [], "created": "2026-09-23T11:50:40.039Z", "modified": "2026-09-23T11:50:40.061Z"}, {"entity": "publication", "iuid": "2f16e19f50e84f20af1f23f998bc1e04", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/2f16e19f50e84f20af1f23f998bc1e04.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/2f16e19f50e84f20af1f23f998bc1e04"}}, "title": "Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting.", "authors": [{"family": "Nilsson", "given": "Christer", "initials": "C"}, {"family": "Huleg\u00e5rdh", "given": "Erik", "initials": "E"}, {"family": "Garelius", "given": "Hege", "initials": "H"}, {"family": "M\u00f6llg\u00e5rd", "given": "Lars", "initials": "L"}, {"family": "Brune", "given": "Mats", "initials": "M"}, {"family": "Wahlin", "given": "Anders", "initials": "A"}, {"family": "Lenhoff", "given": "Stig", "initials": "S"}, {"family": "Fr\u00f6din", "given": "Ulla", "initials": "U"}, {"family": "Remberger", "given": "Mats", "initials": "M"}, {"family": "H\u00f6glund", "given": "Martin", "initials": "M"}, {"family": "Juliusson", "given": "Gunnar", "initials": "G"}, {"family": "Stockelberg", "given": "Dick", "initials": "D"}, {"family": "Lehmann", "given": "S\u00f6ren", "initials": "S"}], "type": "journal article", "published": "2019-09-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "25", "issue": "9", "pages": "1770-1778", "issn-l": null}, "abstract": "Secondary AML (s-AML), including AML with an antecedent hematologic disorder (AHD-AML) and therapy-related AML (t-AML), constitutes a large proportion of patients with AML and is considered to confer a dismal prognosis. The role of allogeneic hematopoietic cell transplantation (HCT) in patients with s-AML and the extent to which HCT is performed in these patients has been little studied to date. We used the population-based Swedish AML Registry comprising 3337 intensively treated adult patients over a 17-year period to study the role of HCT within the group of patients with s-AML as well as compared with patients with de novo AML. HCT was performed in 576 patients (22%) with de novo AML, in 74 patients (17%) with AHD-AML, and in 57 patients (20%) with t-AML. At 5 years after diagnosis, there were no survivors among patients with previous myeloproliferative neoplasms who did not undergo HCT, and corresponding survival for patients with antecedent myelodysplastic syndromes and t-AML was and 2% and 4%, respectively. HCT was compared with chemotherapy consolidation in s-AML using 3 models: (1) a 200-day landmark analysis, in which HCT was favorable compared with conventional consolidation (P = .04, log-rank test); (2) a multivariable Cox regression with HCT as a time-dependent variable, in which the hazard ratio for mortality was 0.73 (95% confidence interval, 0.64 to 0.83) for HCT and favored HCT in all subgroups; and (3) a propensity score matching analysis, in which the 5-year overall survival (OS) and relapse-free survival in patients with s-AML in first complete remission (CR1) was 48% and 43%, respectively, for patients undergoing HCT versus 20% and 21%, respectively, for those receiving chemotherapy consolidation (P = .01 and .02, respectively, log-rank test). Our observational data suggest that HCT improves survival and offers the only realistic curative treatment option in patients with s-AML.", "doi": "10.1016/j.bbmt.2019.05.038", "pmid": "31176789", "labels": [], "xrefs": [{"db": "pii", "key": "S1083-8791(19)30363-5"}], "notes": [], "created": "2026-09-23T09:44:16.795Z", "modified": "2026-09-23T10:18:33.287Z"}, {"entity": "publication", "iuid": "a4e7d204db2347e28aea8d018d91e315", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a4e7d204db2347e28aea8d018d91e315.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a4e7d204db2347e28aea8d018d91e315"}}, "title": "The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.", "authors": [{"family": "Prokopishyn", "given": "Nicole L", "initials": "NL"}, {"family": "Logan", "given": "Brent R", "initials": "BR"}, {"family": "Kiefer", "given": "Deidre M", "initials": "DM"}, {"family": "Sees", "given": "Jennifer A", "initials": "JA"}, {"family": "Chitphakdithai", "given": "Pintip", "initials": "P"}, {"family": "Ahmed", "given": "Ibrahim A", "initials": "IA"}, {"family": "Anderlini", "given": "Paolo N", "initials": "PN"}, {"family": "Beitinjaneh", "given": "Amer M", "initials": "AM"}, {"family": "Bredeson", "given": "Christopher", "initials": "C"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "Chhabra", "given": "Saurabh", "initials": "S"}, {"family": "Daly", "given": "Andrew", "initials": "A"}, {"family": "Diaz", "given": "Miguel Angel", "initials": "MA"}, {"family": "Farhadfar", "given": "Nosha", "initials": "N"}, {"family": "Frangoul", "given": "Haydar A", "initials": "HA"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Gastineau", "given": "Dennis A", "initials": "DA"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "Hale", "given": "Gregory A", "initials": "GA"}, {"family": "Hematti", "given": "Peiman", "initials": "P"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kasow", "given": "Kimberly A", "initials": "KA"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Liesveld", "given": "Jane L", "initials": "JL"}, {"family": "Murthy", "given": "Hemant S", "initials": "HS"}, {"family": "Norkin", "given": "Maxim", "initials": "M"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Papari", "given": "Mona", "initials": "M"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Szer", "given": "Jeffrey", "initials": "J"}, {"family": "Waller", "given": "Edmund K", "initials": "EK"}, {"family": "Wirk", "given": "Baldeep", "initials": "B"}, {"family": "Yared", "given": "Jean A", "initials": "JA"}, {"family": "Pulsipher", "given": "Michael A", "initials": "MA"}, {"family": "Shah", "given": "Nirali N", "initials": "NN"}, {"family": "Switzer", "given": "Galen E", "initials": "GE"}, {"family": "O'Donnell", "given": "Paul V", "initials": "PV"}, {"family": "Confer", "given": "Dennis L", "initials": "DL"}, {"family": "Shaw", "given": "Bronwen E", "initials": "BE"}], "type": "clinical trial", "published": "2019-07-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "25", "issue": "7", "pages": "1325-1330", "issn-l": null}, "abstract": "Bone marrow (BM) is an essential source of hematopoietic stem cell grafts for many allogeneic hematopoietic cell transplant (HCT) recipients, including adult patients (for specific diseases and transplantation strategies) and the majority of pediatric recipient. However, since the advent of granulocyte colony-stimulating factor-mobilized peripheral blood stem cell (PBSC) grafts, there has been a significant decrease in the use of BM in HCT, thought to be due mainly to the increased logistical challenges in harvesting BM compared with PBSCs, as well as generally no significant survival advantage of BM over PBSCs. The decreased frequency of collection has the potential to impact the quality of BM harvests. In this study, we examined >15,000 BM donations collected at National Marrow Donor Program centers between 1994 and 2016 and found a significant decline in the quality of BM products, as defined by the concentration of total nucleated cells (TNCs). The mean TNC concentration in BM donations dropped from 21.8 \u00d7 106 cells/mL in the earliest era (1994 to 1996) to 18.7 \u00d7 106 cells/mL in the most recent era (2012 to 2016) (means ratio, .83; P < .001). This decline in BM quality was seen despite the selection of more donors perceived to be optimal (eg, younger and male). Multivariate regression analysis showed that higher-volume centers (performing >30 collections per era) had better-quality harvests with higher concentrations of TNCs collected. In conclusion, we have identified a significant decrease in the quality of BM collections over time, and lower-volume collection centers had poorer-quality harvests. In this analysis, we could not elucidate the direct cause for this finding, suggesting the need for further studies to investigate the key factors responsible and to explore the impact on transplant recipients.", "doi": "10.1016/j.bbmt.2019.01.034", "pmid": "30716454", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1522897"}, {"db": "pmc", "key": "PMC6615955"}, {"db": "pii", "key": "S1083-8791(19)30092-8"}], "notes": [], "created": "2026-09-23T10:08:58.172Z", "modified": "2026-09-23T10:47:10.919Z"}, {"entity": "publication", "iuid": "d61eb9bb04a945d9a75289342df87048", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/d61eb9bb04a945d9a75289342df87048.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/d61eb9bb04a945d9a75289342df87048"}}, "title": "Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.", "authors": [{"family": "Norkin", "given": "Maxim", "initials": "M"}, {"family": "Shaw", "given": "Bronwen E", "initials": "BE"}, {"family": "Brazauskas", "given": "Ruta", "initials": "R"}, {"family": "Tecca", "given": "Heather R", "initials": "HR"}, {"family": "Leather", "given": "Helen L", "initials": "HL"}, {"family": "Gea-Banacloche", "given": "Juan", "initials": "J"}, {"family": "T Kamble", "given": "Rammurti", "initials": "R"}, {"family": "DeFilipp", "given": "Zachariah", "initials": "Z"}, {"family": "Jacobsohn", "given": "David A", "initials": "DA"}, {"family": "Ringden", "given": "Olle", "initials": "O"}, {"family": "Inamoto", "given": "Yoshihiro", "initials": "Y"}, {"family": "A Kasow", "given": "Kimberly", "initials": "K"}, {"family": "Buchbinder", "given": "David", "initials": "D"}, {"family": "Shaw", "given": "Peter", "initials": "P"}, {"family": "Hematti", "given": "Peiman", "initials": "P"}, {"family": "Schears", "given": "Raquel", "initials": "R"}, {"family": "Badawy", "given": "Sherif M", "initials": "SM"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Bhatt", "given": "Neel", "initials": "N"}, {"family": "Horn", "given": "Biljana", "initials": "B"}, {"family": "Chhabra", "given": "Saurabh", "initials": "S"}, {"family": "M Page", "given": "Kristin", "initials": "K"}, {"family": "Hamilton", "given": "Betty", "initials": "B"}, {"family": "Hildebrandt", "given": "Gerhard C", "initials": "GC"}, {"family": "Yared", "given": "Jean A", "initials": "JA"}, {"family": "Agrawal", "given": "Vaibhav", "initials": "V"}, {"family": "M Beitinjaneh", "given": "Amer", "initials": "A"}, {"family": "Majhail", "given": "Navneet", "initials": "N"}, {"family": "Kindwall-Keller", "given": "Tamila", "initials": "T"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Schoemans", "given": "Helene", "initials": "H"}, {"family": "Gale", "given": "Robert Peter", "initials": "RP"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "A Ahmed", "given": "Ibrahim", "initials": "I"}, {"family": "Schouten", "given": "Harry C", "initials": "HC"}, {"family": "L Liesveld", "given": "Jane", "initials": "J"}, {"family": "Khera", "given": "Nandita", "initials": "N"}, {"family": "Steinberg", "given": "Amir", "initials": "A"}, {"family": "Shah", "given": "Ami J", "initials": "AJ"}, {"family": "Solh", "given": "Melhem", "initials": "M"}, {"family": "Marks", "given": "David I", "initials": "DI"}, {"family": "Rybka", "given": "Witold", "initials": "W"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Dietz", "given": "Andrew C", "initials": "AC"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "George", "given": "Biju", "initials": "B"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Flowers", "given": "Mary E D", "initials": "MED"}, {"family": "Battiwalla", "given": "Minoo", "initials": "M"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Riches", "given": "Marcie L", "initials": "ML"}, {"family": "Wingard", "given": "John R", "initials": "JR"}], "type": "clinical trial", "published": "2019-02-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "25", "issue": "2", "pages": "362-368", "issn-l": null}, "abstract": "We analyzed late fatal infections (LFIs) in allogeneic stem cell transplantation (HCT) recipients reported to the Center for International Blood and Marrow Transplant Research. We analyzed the incidence, infection types, and risk factors contributing to LFI in 10,336 adult and 5088 pediatric subjects surviving for \u22652 years after first HCT without relapse. Among 2245 adult and 377 pediatric patients who died, infections were a primary or contributory cause of death in 687 (31%) and 110 (29%), respectively. At 12 years post-HCT, the cumulative incidence of LFIs was 6.4% (95% confidence interval [CI], 5.8% to 7.0%) in adults, compared with 1.8% (95% CI, 1.4% to 2.3%) in pediatric subjects; P < .001). In adults, the 2 most significant risks for developing LFI were increasing age (20 to 39, 40 to 54, and \u226555 years versus 18 to 19 years) with hazard ratios (HRs) of 3.12 (95% CI, 1.33 to 7.32), 3.86 (95% CI, 1.66 to 8.95), and 5.49 (95% CI, 2.32 to 12.99) and a history of chronic graft-versus-host disease GVHD (cGVHD) with ongoing immunosuppression at 2 years post-HCT compared with no history of GVHD with (HR, 3.87; 95% CI, 2.59 to 5.78). In pediatric subjects, the 3 most significant risks for developing LFI were a history of cGVHD with ongoing immunosuppression (HR, 9.49; 95% CI, 4.39 to 20.51) or without ongoing immunosuppression (HR, 2.7; 95% CI, 1.05 to 7.43) at 2 years post-HCT compared with no history of GVHD, diagnosis of inherited abnormalities of erythrocyte function compared with diagnosis of acute myelogenous leukemia (HR, 2.30; 95% CI, 1.19 to 4.42), and age >10 years (HR, 1.92; 95% CI, 1.15 to 3.2). This study emphasizes the importance of continued vigilance for late infections after HCT and institution of support strategies aimed at decreasing the risk of cGVHD.", "doi": "10.1016/j.bbmt.2018.09.031", "pmid": "30287390", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1508606"}, {"db": "pmc", "key": "PMC6339825"}, {"db": "pii", "key": "S1083-8791(18)30598-6"}], "notes": [], "created": "2026-09-23T09:18:52.025Z", "modified": "2026-09-23T09:18:52.052Z"}, {"entity": "publication", "iuid": "1699795e4671464ab3635b40007c4652", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/1699795e4671464ab3635b40007c4652.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/1699795e4671464ab3635b40007c4652"}}, "title": "Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.", "authors": [{"family": "Wood", "given": "William A", "initials": "WA"}, {"family": "Brazauskas", "given": "Ruta", "initials": "R"}, {"family": "Hu", "given": "Zhen-Huan", "initials": "ZH"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Ahmed", "given": "Ibrahim A", "initials": "IA"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Badawy", "given": "Sherif", "initials": "S"}, {"family": "Beitinjaneh", "given": "Amer", "initials": "A"}, {"family": "George", "given": "Biju", "initials": "B"}, {"family": "Buchbinder", "given": "David", "initials": "D"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "Dedeken", "given": "Laurence", "initials": "L"}, {"family": "Diaz", "given": "Miguel Angel", "initials": "MA"}, {"family": "Freytes", "given": "Cesar O", "initials": "CO"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "Almaguer", "given": "David Gomez", "initials": "DG"}, {"family": "Gupta", "given": "Ashish", "initials": "A"}, {"family": "Hale", "given": "Gregory", "initials": "G"}, {"family": "Hashmi", "given": "Shahrukh K", "initials": "SK"}, {"family": "Inamoto", "given": "Yoshihiro", "initials": "Y"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Adekola", "given": "Kehinde", "initials": "K"}, {"family": "Kindwall-Keller", "given": "Tamila", "initials": "T"}, {"family": "Knight", "given": "Jennifer", "initials": "J"}, {"family": "Kumar", "given": "Lalit", "initials": "L"}, {"family": "Kuwatsuka", "given": "Yachiyo", "initials": "Y"}, {"family": "Law", "given": "Jason", "initials": "J"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "LeMaistre", "given": "Charles", "initials": "C"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Pulsipher", "given": "Michael A", "initials": "MA"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Schultz", "given": "Kirk R", "initials": "KR"}, {"family": "Saad", "given": "Ayman A", "initials": "AA"}, {"family": "Seftel", "given": "Matthew", "initials": "M"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Shea", "given": "Thomas C", "initials": "TC"}, {"family": "Steinberg", "given": "Amir", "initials": "A"}, {"family": "Sullivan", "given": "Keith", "initials": "K"}, {"family": "Szwajcer", "given": "David", "initials": "D"}, {"family": "Wirk", "given": "Baldeep", "initials": "B"}, {"family": "Yared", "given": "Jean", "initials": "J"}, {"family": "Yong", "given": "Agnes", "initials": "A"}, {"family": "Dalal", "given": "Jignesh", "initials": "J"}, {"family": "Hahn", "given": "Theresa", "initials": "T"}, {"family": "Khera", "given": "Nandita", "initials": "N"}, {"family": "Bonfim", "given": "Carmem", "initials": "C"}, {"family": "Atsuta", "given": "Yoshiko", "initials": "Y"}, {"family": "Saber", "given": "Wael", "initials": "W"}], "type": "journal article", "published": "2018-09-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "24", "issue": "9", "pages": "1928-1935", "issn-l": null}, "abstract": "For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. The impact of country-level economic conditions on post-transplantation outcomes is not known. Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL. Using data from the Center for Blood and Marrow Transplant Research, we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013. Cox regression models were constructed using the following macroeconomic indicators as main effects: Gross national income per capita, health expenditure per capita, and Human Development Index (HDI). The outcome was overall survival at 100 days following transplantation. In each model, transplants performed within lower resourced environments were associated with inferior overall survival. In the model with the HDI as the main effect, transplants performed in the lowest HDI quartile (n = 697) were associated with increased hazard for mortality (hazard ratio, 2.42; 95% confidence interval, 1.64 to 3.57; P < .001) in comparison with transplants performed in the countries with the highest HDI quartile. This translated into an 11% survival difference at 100 days (77% for lowest HDI quartile versus 88% for all other quartiles). Country-level macroeconomic indices were associated with lower survival at 100 days after alloHCT for ALL. The reasons for this disparity require further investigation.", "doi": "10.1016/j.bbmt.2018.03.016", "pmid": "29567340", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS963529"}, {"db": "pmc", "key": "PMC6146070"}, {"db": "pii", "key": "S1083-8791(18)30129-0"}], "notes": [], "created": "2026-09-23T13:12:47.316Z", "modified": "2026-09-23T13:12:47.340Z"}, {"entity": "publication", "iuid": "25fb0af7d2274d42970db6950aa799d8", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/25fb0af7d2274d42970db6950aa799d8.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/25fb0af7d2274d42970db6950aa799d8"}}, "title": "Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.", "authors": [{"family": "Casulo", "given": "Carla", "initials": "C"}, {"family": "Friedberg", "given": "Jonathan W", "initials": "JW"}, {"family": "Ahn", "given": "Kwang W", "initials": "KW"}, {"family": "Flowers", "given": "Christopher", "initials": "C"}, {"family": "DiGilio", "given": "Alyssa", "initials": "A"}, {"family": "Smith", "given": "Sonali M", "initials": "SM"}, {"family": "Ahmed", "given": "Sairah", "initials": "S"}, {"family": "Inwards", "given": "David", "initials": "D"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Chen", "given": "Andy I", "initials": "AI"}, {"family": "Choe", "given": "Hannah", "initials": "H"}, {"family": "Cohen", "given": "Jonathon", "initials": "J"}, {"family": "Copelan", "given": "Edward", "initials": "E"}, {"family": "Farooq", "given": "Umar", "initials": "U"}, {"family": "Fenske", "given": "Timothy S", "initials": "TS"}, {"family": "Freytes", "given": "Cesar", "initials": "C"}, {"family": "Gaballa", "given": "Sameh", "initials": "S"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Jethava", "given": "Yogesh", "initials": "Y"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kenkre", "given": "Vaishalee P", "initials": "VP"}, {"family": "Lazarus", "given": "Hillard", "initials": "H"}, {"family": "Lazaryan", "given": "Aleksandr", "initials": "A"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Rezvani", "given": "Andrew R", "initials": "AR"}, {"family": "Rizzieri", "given": "David", "initials": "D"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Shah", "given": "Gunjan L", "initials": "GL"}, {"family": "Shah", "given": "Nina", "initials": "N"}, {"family": "Solh", "given": "Melham", "initials": "M"}, {"family": "Sureda", "given": "Anna", "initials": "A"}, {"family": "William", "given": "Basem", "initials": "B"}, {"family": "Cumpston", "given": "Aaron", "initials": "A"}, {"family": "Zelenetz", "given": "Andrew D", "initials": "AD"}, {"family": "Link", "given": "Brian K", "initials": "BK"}, {"family": "Hamadani", "given": "Mehdi", "initials": "M"}], "type": "journal article", "published": "2018-06-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "24", "issue": "6", "pages": "1163-1171", "issn-l": null}, "abstract": "Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (\u22641 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.", "doi": "10.1016/j.bbmt.2017.12.771", "pmid": "29242111", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS940349"}, {"db": "pmc", "key": "PMC5993598"}, {"db": "pii", "key": "S1083-8791(17)31675-0"}], "notes": [], "created": "2026-09-23T07:29:49.631Z", "modified": "2026-09-23T07:29:49.693Z"}, {"entity": "publication", "iuid": "a0e275b85c6f437fa7ab5cc228b08452", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a0e275b85c6f437fa7ab5cc228b08452.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a0e275b85c6f437fa7ab5cc228b08452"}}, "title": "Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.", "authors": [{"family": "Bejanyan", "given": "Nelli", "initials": "N"}, {"family": "Zhang", "given": "Mei-Jie", "initials": "MJ"}, {"family": "Wang", "given": "Hai-Lin", "initials": "HL"}, {"family": "Lazaryan", "given": "Aleksandr", "initials": "A"}, {"family": "de Lima", "given": "Marcos", "initials": "M"}, {"family": "Marks", "given": "David I", "initials": "DI"}, {"family": "Sandmaier", "given": "Brenda M", "initials": "BM"}, {"family": "Bachanova", "given": "Veronika", "initials": "V"}, {"family": "Rowe", "given": "Jacob", "initials": "J"}, {"family": "Tallman", "given": "Martin", "initials": "M"}, {"family": "Kebriaei", "given": "Partow", "initials": "P"}, {"family": "Kharfan-Dabaja", "given": "Mohamed", "initials": "M"}, {"family": "Peter Gale", "given": "Robert", "initials": "R"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Ustun", "given": "Celalettin", "initials": "C"}, {"family": "Copelan", "given": "Edward", "initials": "E"}, {"family": "Ky Hamilton", "given": "Betty", "initials": "B"}, {"family": "Schiller", "given": "Gary", "initials": "G"}, {"family": "Hogan", "given": "William", "initials": "W"}, {"family": "Hashmi", "given": "Shahrukh", "initials": "S"}, {"family": "Seftel", "given": "Matthew", "initials": "M"}, {"family": "Kanakry", "given": "Christopher G", "initials": "CG"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Martino", "given": "Rodrigo", "initials": "R"}, {"family": "Saber", "given": "Wael", "initials": "W"}, {"family": "Khoury", "given": "H Jean", "initials": "HJ"}, {"family": "Weisdorf", "given": "Daniel J", "initials": "DJ"}], "type": "comparative study", "published": "2018-05-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "24", "issue": "5", "pages": "945-955", "issn-l": null}, "abstract": "Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received \u22652 (n = 109), 1 (n = 93), or 0 cycles (n = 322) of consolidation before myeloablative alloHCT from 2008 to 2012. As expected, time to alloHCT was longer with increasing cycles of consolidation. Patients receiving \u22652, 1, or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20%, 27%, and 22%; 1-year transplant-related mortality (TRM) of 16%, 18%, and 23%; adjusted 3-year leukemia-free survival (LFS) of 54%, 48%, and 47%; and 3-year overall survival (OS) of 63%, 59%, and 54% (all P values >.40). Multivariable analysis confirmed that consolidation was not prognostic for LFS (relative risk, 1.20, 95% confidence interval, .86 to 1.67; P = .28 for no consolidation; RR, 1.18, 95% confidence interval, .79 to 1.76; P = .41 for 1 cycle versus \u22652 cycles = reference). Similarly, consolidation was not associated with OS, relapse, TRM, or graft-versus-host disease. We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.", "doi": "10.1016/j.bbmt.2017.12.784", "pmid": "29275139", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS941192"}, {"db": "pmc", "key": "PMC5953798"}, {"db": "pii", "key": "S1083-8791(17)31710-X"}], "notes": [], "created": "2026-09-23T13:04:16.699Z", "modified": "2026-09-23T13:04:16.727Z"}, {"entity": "publication", "iuid": "a7a36913904e48508b6583e007659141", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a7a36913904e48508b6583e007659141.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a7a36913904e48508b6583e007659141"}}, "title": "Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.", "authors": [{"family": "Qayed", "given": "Muna", "initials": "M"}, {"family": "Wang", "given": "Tao", "initials": "T"}, {"family": "Hemmer", "given": "Michael T", "initials": "MT"}, {"family": "Spellman", "given": "Stephen", "initials": "S"}, {"family": "Arora", "given": "Mukta", "initials": "M"}, {"family": "Couriel", "given": "Daniel", "initials": "D"}, {"family": "Alousi", "given": "Amin", "initials": "A"}, {"family": "Pidala", "given": "Joseph", "initials": "J"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Ayas", "given": "Mouhab", "initials": "M"}, {"family": "Bitan", "given": "Menachem", "initials": "M"}, {"family": "Cairo", "given": "Mitchell", "initials": "M"}, {"family": "Choi", "given": "Sung Won", "initials": "SW"}, {"family": "Dandoy", "given": "Christopher", "initials": "C"}, {"family": "Delgado", "given": "David", "initials": "D"}, {"family": "Gale", "given": "Robert Peter", "initials": "RP"}, {"family": "Hale", "given": "Gregory", "initials": "G"}, {"family": "Frangoul", "given": "Haydar", "initials": "H"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kharfan-Dabaja", "given": "Mohamed", "initials": "M"}, {"family": "Lehman", "given": "Leslie", "initials": "L"}, {"family": "Levine", "given": "John", "initials": "J"}, {"family": "MacMillan", "given": "Margaret", "initials": "M"}, {"family": "Marks", "given": "David I", "initials": "DI"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Hematti", "given": "Peiman", "initials": "P"}, {"family": "Ringden", "given": "Olov", "initials": "O"}, {"family": "Saad", "given": "Ayman", "initials": "A"}, {"family": "Satwani", "given": "Prakash", "initials": "P"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Schultz", "given": "Kirk R", "initials": "KR"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Shenoy", "given": "Shalini", "initials": "S"}, {"family": "Waller", "given": "Edmund K", "initials": "EK"}, {"family": "Yu", "given": "Lolie", "initials": "L"}, {"family": "Horowitz", "given": "Mary M", "initials": "MM"}, {"family": "Horan", "given": "John", "initials": "J"}], "type": "clinical trial", "published": "2018-03-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "24", "issue": "3", "pages": "521-528", "issn-l": null}, "abstract": "Relapse remains the major cause of mortality after hematopoietic cell transplantation (HCT) for pediatric acute leukemia. Previous research has suggested that reducing the intensity of calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis may be an effective strategy for abrogating the risk of relapse in pediatric patients undergoing matched sibling donor (MSD) HCT. We reasoned that the benefits of this strategy could be maximized by selectively applying it to those patients least likely to develop GVHD. We conducted a study of risk factors for GVHD, to risk-stratify patients based on age. Patients age <18 years with leukemia who received myeloablative, T cell-replete MSD bone marrow transplantation and calcineurin inhibitor-based GVHD prophylaxis between 2000 and 2013 and were entered into the Center for International Blood and Marrow Transplant Research registry were included. The cumulative incidence of grade II-IV acute GVHD (aGVHD) was 19%, that of grade II-IV aGVHD 7%, and that of chronic GVHD (cGVHD) was 16%. Compared with age 13 to 18 years, age 2 to 12 years was associated with a lower risk of grade II-IV aGVHD (hazard ratio [HR], .42; 95% confidence interval [CI], .26 to .70; P = .0008), grade II-IV aGVHD (HR, .24; 95% CI, .10 to .56; P = .001), and cGVHD (HR, .32; 95% CI, .19 to .54; P < .001). Compared with 2000-2004, the risk of grade II-IV aGVHD was lower in children undergoing transplantation in 2005-2008 (HR, .36; 95% CI, .20 to .65; P = .0007) and in 2009-2013 (HR, .24; 95% CI. .11 to .53; P = .0004). Similarly, the risk of grade III-IV aGVHD was lower in children undergoing transplantation in 2005-2008 (HR, .23; 95% CI, .08 to .65; P = .0056) and 2009-2013 (HR, .16; 95% CI, .04 to .67; P = .0126) compared with those doing so in 2000-2004. We conclude that aGVHD rates have decreased significantly over time, and that children age 2 to 12 years are at very low risk for aGVHD and cGVHD. These results should be validated in an independent analysis, because these patients with high-risk malignancies may be good candidates for trials of reduced GVHD prophylaxis.", "doi": "10.1016/j.bbmt.2017.11.004", "pmid": "29155316", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS921679"}, {"db": "pmc", "key": "PMC5826854"}, {"db": "pii", "key": "S1083-8791(17)30818-2"}], "notes": [], "created": "2026-09-23T09:19:44.049Z", "modified": "2026-09-23T09:19:44.061Z"}, {"entity": "publication", "iuid": "dbe8e97b618a45dcbec78aa1f6521918", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/dbe8e97b618a45dcbec78aa1f6521918.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/dbe8e97b618a45dcbec78aa1f6521918"}}, "title": "Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.", "authors": [{"family": "Hill", "given": "Brian T", "initials": "BT"}, {"family": "Ahn", "given": "Kwang Woo", "initials": "KW"}, {"family": "Hu", "given": "Zhen-Huan", "initials": "ZH"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Beitinjaneh", "given": "Amer", "initials": "A"}, {"family": "Cahn", "given": "Jean-Yves", "initials": "JY"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "Kharfan-Dabaja", "given": "Mohamed A", "initials": "MA"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Ghosh", "given": "Nilanjan", "initials": "N"}, {"family": "Grunwald", "given": "Michael R", "initials": "MR"}, {"family": "Inamoto", "given": "Yoshihiro", "initials": "Y"}, {"family": "Kindwall-Keller", "given": "Tamila", "initials": "T"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Saad", "given": "Ayman", "initials": "A"}, {"family": "Seftel", "given": "Matthew", "initials": "M"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Szer", "given": "Jeffrey", "initials": "J"}, {"family": "Tallman", "given": "Martin", "initials": "M"}, {"family": "Ustun", "given": "Celalettin", "initials": "C"}, {"family": "Wiernik", "given": "Peter H", "initials": "PH"}, {"family": "Maziarz", "given": "Richard T", "initials": "RT"}, {"family": "Kalaycio", "given": "Matt", "initials": "M"}, {"family": "Alyea", "given": "Edwin", "initials": "E"}, {"family": "Popat", "given": "Uday", "initials": "U"}, {"family": "Sobecks", "given": "Ronald", "initials": "R"}, {"family": "Saber", "given": "Wael", "initials": "W"}], "type": "journal article", "published": "2018-03-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "24", "issue": "3", "pages": "581-586", "issn-l": null}, "abstract": "Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplantation (allo-HCT) for medically fit patients. Although the use of allo-HCT has declined since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT, the only known curative treatment for CLL. The potential benefit of transplantation is most likely due to the presence of alloreactive donor T cells that mediate the graft-versus-leukemia (GVL) effect. The recognition of potentially tumor-specific antigens in the context of class I and II major histocompatibility complex on malignant B lymphocytes by donor T cells may be influenced by subtle differences in the highly polymorphic HLA locus. Given previous reports of specific HLA alleles impacting the incidence of CLL and the clinical outcomes of allo-HCT for CLL, we sought to study the overall survival and progression-free survival of a large cohort of patients with CLL who underwent allo-HCT from fully HLA-matched related and unrelated donors at Center for International Blood and Marrow Transplant Research transplantation centers. We found no statistically significant association of allo-HCT outcomes in CLL based on previously reported HLA combinations. Additional study is needed to further define the immunologic features that portend a more favorable GVL effect after allo-HCT for CLL.", "doi": "10.1016/j.bbmt.2017.10.015", "pmid": "29032274", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS941902"}, {"db": "pmc", "key": "PMC5944847"}, {"db": "pii", "key": "S1083-8791(17)30774-7"}], "notes": [], "created": "2026-09-23T13:26:41.582Z", "modified": "2026-09-23T13:26:41.612Z"}, {"entity": "publication", "iuid": "06dcfce584bb44b4a8be36ecb13fdfce", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/06dcfce584bb44b4a8be36ecb13fdfce.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/06dcfce584bb44b4a8be36ecb13fdfce"}}, "title": "Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report.", "authors": [{"family": "Khandelwal", "given": "Pooja", "initials": "P"}, {"family": "Millard", "given": "Heather R", "initials": "HR"}, {"family": "Thiel", "given": "Elizabeth", "initials": "E"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Abraham", "given": "Allistair A", "initials": "AA"}, {"family": "Auletta", "given": "Jeffery J", "initials": "JJ"}, {"family": "Boulad", "given": "Farid", "initials": "F"}, {"family": "Brown", "given": "Valerie I", "initials": "VI"}, {"family": "Camitta", "given": "Bruce M", "initials": "BM"}, {"family": "Chan", "given": "Ka Wah", "initials": "KW"}, {"family": "Chaudhury", "given": "Sonali", "initials": "S"}, {"family": "Cowan", "given": "Morton J", "initials": "MJ"}, {"family": "Angel-Diaz", "given": "Miguel", "initials": "M"}, {"family": "Gadalla", "given": "Shahinaz M", "initials": "SM"}, {"family": "Gale", "given": "Robert Peter", "initials": "RP"}, {"family": "Hale", "given": "Gregory", "initials": "G"}, {"family": "Kasow", "given": "Kimberly A", "initials": "KA"}, {"family": "Keating", "given": "Amy K", "initials": "AK"}, {"family": "Kitko", "given": "Carrie L", "initials": "CL"}, {"family": "MacMillan", "given": "Margaret L", "initials": "ML"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Page", "given": "Kristin M", "initials": "KM"}, {"family": "Seber", "given": "Adriana", "initials": "A"}, {"family": "Smith", "given": "Angela R", "initials": "AR"}, {"family": "Warwick", "given": "Anne B", "initials": "AB"}, {"family": "Wirk", "given": "Baldeep", "initials": "B"}, {"family": "Mehta", "given": "Parinda A", "initials": "PA"}], "type": "journal article", "published": "2017-08-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "23", "issue": "8", "pages": "1342-1349", "issn-l": null}, "abstract": "This Center for International Blood and Marrow Transplant Research report describes the use of hematopoietic stem cell transplantation (HSCT) in pediatric patients with cancer, 4408 undergoing allogeneic (allo) and3076 undergoing autologous (auto) HSCT in the United States between 2008 and 2014. In both settings, there was a greater proportion of boys (n = 4327; 57%), children < 10 years of age (n = 4412; 59%), whites (n = 5787; 77%), and children with a performance score \u2265 90% at HSCT (n = 6187; 83%). Leukemia was the most common indication for an allo-transplant (n = 4170; 94%), and among these, acute lymphoblastic leukemia in second complete remission (n = 829; 20%) and acute myeloid leukemia in first complete remission (n = 800; 19%) werethe most common. The most frequently used donor relation, stem cell sources, and HLA match were unrelated donor (n = 2933; 67%), bone marrow (n = 2378; 54%), and matched at 8/8 HLA antigens (n = 1098; 37%) respectively. Most allo-transplants used myeloablative conditioning (n = 4070; 92%) and calcineurin inhibitors and methotrexate (n = 2245; 51%) for acute graft-versus-host disease prophylaxis. Neuroblastoma was the most common primary neoplasm for an auto-transplant (n = 1338; 44%). Tandem auto-transplants for neuroblastoma declined after 2012 (40% in 2011, 25% in 2012, and 8% in 2014), whereas tandem auto-transplants increased for brain tumors (57% in 2008 and 77% in 2014). Allo-transplants from relatives other than HLA-identical siblings doubled between 2008 and 2014 (3% in 2008 and 6% in 2014). These trends will be monitored in future reports of transplant practices in the United States.", "doi": "10.1016/j.bbmt.2017.04.018", "pmid": "28450183", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS888868"}, {"db": "pmc", "key": "PMC5669065"}, {"db": "pii", "key": "S1083-8791(17)30427-5"}], "notes": [], "created": "2026-09-23T09:17:32.946Z", "modified": "2026-09-23T09:17:32.978Z"}, {"entity": "publication", "iuid": "268f8cd7903748f5b5851102da869fc4", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/268f8cd7903748f5b5851102da869fc4.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/268f8cd7903748f5b5851102da869fc4"}}, "title": "Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.", "authors": [{"family": "Vrooman", "given": "Lynda M", "initials": "LM"}, {"family": "Millard", "given": "Heather R", "initials": "HR"}, {"family": "Brazauskas", "given": "Ruta", "initials": "R"}, {"family": "Majhail", "given": "Navneet S", "initials": "NS"}, {"family": "Battiwalla", "given": "Minoo", "initials": "M"}, {"family": "Flowers", "given": "Mary E", "initials": "ME"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Akpek", "given": "G\u00f6rg\u00fcn", "initials": "G"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Bajwa", "given": "Rajinder", "initials": "R"}, {"family": "Baker", "given": "K Scott", "initials": "KS"}, {"family": "Beitinjaneh", "given": "Amer", "initials": "A"}, {"family": "Bitan", "given": "Menachem", "initials": "M"}, {"family": "Buchbinder", "given": "David", "initials": "D"}, {"family": "Chow", "given": "Eric", "initials": "E"}, {"family": "Dandoy", "given": "Christopher", "initials": "C"}, {"family": "Dietz", "given": "Andrew C", "initials": "AC"}, {"family": "Diller", "given": "Lisa", "initials": "L"}, {"family": "Gale", "given": "Robert Peter", "initials": "RP"}, {"family": "Hashmi", "given": "Shahrukh K", "initials": "SK"}, {"family": "Hayashi", "given": "Robert J", "initials": "RJ"}, {"family": "Hematti", "given": "Peiman", "initials": "P"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kasow", "given": "Kimberly A", "initials": "KA"}, {"family": "Kletzel", "given": "Morris", "initials": "M"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Malone", "given": "Adriana K", "initials": "AK"}, {"family": "Marks", "given": "David I", "initials": "DI"}, {"family": "O'Brien", "given": "Tracey A", "initials": "TA"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Ringden", "given": "Olle", "initials": "O"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Steinberg", "given": "Amir", "initials": "A"}, {"family": "Yu", "given": "Lolie C", "initials": "LC"}, {"family": "Warwick", "given": "Anne", "initials": "A"}, {"family": "Shaw", "given": "Bronwen", "initials": "B"}, {"family": "Duncan", "given": "Christine", "initials": "C"}], "type": "journal article", "published": "2017-08-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "23", "issue": "8", "pages": "1327-1334", "issn-l": null}, "abstract": "Very young children undergoing hematopoietic cell transplantation (HCT) are a unique and vulnerable population. We analyzed outcomes of 717 patients from 117 centers who survived relapse free for \u22651 year after allogeneic myeloablative HCT for hematologic malignancy at <3 years of age, between 1987 and 2012. The median follow-up was 8.3 years (range, 1.0 to 26.4 years); median age at follow-up was 9 years (range, 2 to 29 years). Ten-year overall and relapse-free survival were 87% (95% confidence interval [CI], 85% to 90%) and 84% (95% CI, 81% to 87%). Ten-year cumulative incidence of relapse was 11% (95% CI, 9% to 13%). Of 84 deaths, relapse was the leading cause (43%). Chronic graft-versus-host-disease 1 year after HCT was associated with increased risk of mortality (hazard ratio [HR], 2.1; 95% CI, 1.3 to 3.3; P = .0018). Thirty percent of patients experienced \u22651 organ toxicity/late effect >1 year after HCT. The most frequent late effects included growth hormone deficiency/growth disturbance (10-year cumulative incidence, 23%; 95% CI, 19% to 28%), cataracts (18%; 95% CI, 15% to 22%), hypothyroidism (13%; 95% CI, 10% to 16%), gonadal dysfunction/infertility requiring hormone replacement (3%; 95% CI, 2% to 5%), and stroke/seizure (3%; 95% CI, 2% to 5%). Subsequent malignancy was reported in 3.6%. In multivariable analysis, total body irradiation (TBI) was predictive of increased risk of cataracts (HR, 17.2; 95% CI, 7.4 to 39.8; P < .001), growth deficiency (HR, 3.5; 95% CI, 2.2 to 5.5; P < .001), and hypothyroidism (HR, 5.3; 95% CI, 3.0 to 9.4; P < .001). In summary, those who survived relapse free \u22651 year after HCT for hematologic malignancy at <3 years of age had favorable overall survival. Chronic graft-versus-host-disease and TBI were associated with adverse outcomes. Future efforts should focus on reducing the risk of relapse and late effects after HCT at early age.", "doi": "10.1016/j.bbmt.2017.04.017", "pmid": "28461213", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS888867"}, {"db": "pmc", "key": "PMC5666571"}, {"db": "pii", "key": "S1083-8791(17)30426-3"}], "notes": [], "created": "2026-09-23T09:18:36.867Z", "modified": "2026-09-23T09:18:36.882Z"}, {"entity": "publication", "iuid": "af6b127dc9984423b79fd41a4a434621", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/af6b127dc9984423b79fd41a4a434621.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/af6b127dc9984423b79fd41a4a434621"}}, "title": "Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.", "authors": [{"family": "Gerds", "given": "Aaron T", "initials": "AT"}, {"family": "Woo Ahn", "given": "Kwang", "initials": "K"}, {"family": "Hu", "given": "Zhen-Huan", "initials": "ZH"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Akpek", "given": "Gorgun", "initials": "G"}, {"family": "Aljurf", "given": "Mahmoud", "initials": "M"}, {"family": "Ballen", "given": "Karen K", "initials": "KK"}, {"family": "Beitinjaneh", "given": "Amer", "initials": "A"}, {"family": "Bacher", "given": "Ulrike", "initials": "U"}, {"family": "Cahn", "given": "Jean-Yves", "initials": "JY"}, {"family": "Chhabra", "given": "Saurabh", "initials": "S"}, {"family": "Cutler", "given": "Corey", "initials": "C"}, {"family": "Daly", "given": "Andrew", "initials": "A"}, {"family": "DeFilipp", "given": "Zachariah", "initials": "Z"}, {"family": "Gale", "given": "Robert Peter", "initials": "RP"}, {"family": "Gergis", "given": "Usama", "initials": "U"}, {"family": "Grunwald", "given": "Michael R", "initials": "MR"}, {"family": "Hale", "given": "Gregory A", "initials": "GA"}, {"family": "Hamilton", "given": "Betty Ky", "initials": "BK"}, {"family": "Jagasia", "given": "Madan", "initials": "M"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kindwall-Keller", "given": "Tamila", "initials": "T"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Ramanathan", "given": "Muthalagu", "initials": "M"}, {"family": "Saad", "given": "Ayman A", "initials": "AA"}, {"family": "Solh", "given": "Melhem", "initials": "M"}, {"family": "Ustun", "given": "Celalettin", "initials": "C"}, {"family": "Valc\u00e1rcel", "given": "David", "initials": "D"}, {"family": "Warlick", "given": "Erica", "initials": "E"}, {"family": "Wirk", "given": "Baldeep M", "initials": "BM"}, {"family": "Kalaycio", "given": "Matt", "initials": "M"}, {"family": "Alyea", "given": "Edwin", "initials": "E"}, {"family": "Popat", "given": "Uday", "initials": "U"}, {"family": "Sobecks", "given": "Ronald", "initials": "R"}, {"family": "Saber", "given": "Wael", "initials": "W"}], "type": "journal article", "published": "2017-06-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "23", "issue": "6", "pages": "971-979", "issn-l": null}, "abstract": "For patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, umbilical cord blood transplantation (UCBT) has become an acceptable alternative donor source in the absence of a matched sibling or unrelated donor. To date, however, there have been few published series dedicated solely to describing the outcomes of adult patients with myelodysplastic syndrome (MDS) who have undergone UCBT. Between 2004 and 2013, 176 adults with MDS underwent UCBT as reported to the Center for International Blood and Marrow Transplant Research. Median age at the time of transplantation was 56 years (range, 18-73 years). The study group included 10% with very low, 23% with low, 19% with intermediate, 19% with high, and 13% with very high-risk Revised International Prognostic Scoring System (IPSS-R) scores. The 100-day probability of grade II-IV acute graft-versus-host disease (GVHD) was 38%, and the 3-year probability of chronic GVHD was 28%. The probabilities of relapse and transplantation-related mortality (TRM) at 3 years were 32% and 40%, respectively, leading to a 3-year disease-free survival (DFS) of 28% and an overall survival (OS) of 31%. In multivariate analysis, increasing IPSS-R score at the time of HCT was associated with inferior TRM (P = .0056), DFS (P = .018), and OS (P = .0082), but not with GVHD or relapse. The presence of pretransplantation comorbidities was associated with TRM (P = .001), DFS (P = .02), and OS (P = .001). Reduced-intensity conditioning was associated with increased risk of relapse (relative risk, 3.95; 95% confidence interval, 1.78-8.75; P < .001), and although a higher proportion of myeloablative UCBTs were performed in patients with high-risk disease, the effect of conditioning regimen intensity was the same regardless of IPSS-R score. For some individuals who lack a matched sibling or unrelated donor, UCBT can result in long-term DFS; however, the success of UCBT in this population is hampered by a high rate of TRM.", "doi": "10.1016/j.bbmt.2017.03.014", "pmid": "28288952", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS867817"}, {"db": "pmc", "key": "PMC5474679"}, {"db": "pii", "key": "S1083-8791(17)30333-6"}], "notes": [], "created": "2026-09-23T11:44:02.039Z", "modified": "2026-09-23T11:44:02.063Z"}, {"entity": "publication", "iuid": "f81fcbe2c9924cb99e92129a6cf15144", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/f81fcbe2c9924cb99e92129a6cf15144.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/f81fcbe2c9924cb99e92129a6cf15144"}}, "title": "Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.", "authors": [{"family": "Cornell", "given": "Robert F", "initials": "RF"}, {"family": "D'Souza", "given": "Anita", "initials": "A"}, {"family": "Kassim", "given": "Adetola A", "initials": "AA"}, {"family": "Costa", "given": "Luciano J", "initials": "LJ"}, {"family": "Innis-Shelton", "given": "Racquel D", "initials": "RD"}, {"family": "Zhang", "given": "Mei-Jie", "initials": "MJ"}, {"family": "Huang", "given": "Jiaxing", "initials": "J"}, {"family": "Abidi", "given": "Muneer", "initials": "M"}, {"family": "Aiello", "given": "Jack", "initials": "J"}, {"family": "Akpek", "given": "Gorgun", "initials": "G"}, {"family": "Bashey", "given": "Asad", "initials": "A"}, {"family": "Bashir", "given": "Qaiser", "initials": "Q"}, {"family": "Cerny", "given": "Jan", "initials": "J"}, {"family": "Comenzo", "given": "Raymond", "initials": "R"}, {"family": "Diaz", "given": "Miguel Angel", "initials": "MA"}, {"family": "Freytes", "given": "C\u00e9sar", "initials": "C"}, {"family": "Gale", "given": "Robert Peter", "initials": "RP"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Hamadani", "given": "Mehdi", "initials": "M"}, {"family": "Hashmi", "given": "Shahrukh", "initials": "S"}, {"family": "Holmberg", "given": "Leona", "initials": "L"}, {"family": "Hossain", "given": "Nasheed", "initials": "N"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kharfan-Dabaja", "given": "Mohamed", "initials": "M"}, {"family": "Kindwall-Keller", "given": "Tamila", "initials": "T"}, {"family": "Kyle", "given": "Robert", "initials": "R"}, {"family": "Kumar", "given": "Shaji", "initials": "S"}, {"family": "Lazarus", "given": "Hillard", "initials": "H"}, {"family": "Lee", "given": "Cindy", "initials": "C"}, {"family": "Maiolino", "given": "Angelo", "initials": "A"}, {"family": "Marks", "given": "David I", "initials": "DI"}, {"family": "Meehan", "given": "Kenneth", "initials": "K"}, {"family": "Mikhael", "given": "Joe", "initials": "J"}, {"family": "Nath", "given": "Rajneesh", "initials": "R"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Ramanathan", "given": "Muthalagu", "initials": "M"}, {"family": "Saad", "given": "Ayman", "initials": "A"}, {"family": "Seo", "given": "Sachiko", "initials": "S"}, {"family": "Usmani", "given": "Saad", "initials": "S"}, {"family": "Vesole", "given": "David", "initials": "D"}, {"family": "Vij", "given": "Ravi", "initials": "R"}, {"family": "Vogl", "given": "Dan", "initials": "D"}, {"family": "Wirk", "given": "Baldeep M", "initials": "BM"}, {"family": "Yared", "given": "Jean", "initials": "J"}, {"family": "Krishnan", "given": "Amrita", "initials": "A"}, {"family": "Mark", "given": "Tomer", "initials": "T"}, {"family": "Nieto", "given": "Yago", "initials": "Y"}, {"family": "Hari", "given": "Parameswaran", "initials": "P"}], "type": "comparative study", "published": "2017-02-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "23", "issue": "2", "pages": "269-277", "issn-l": null}, "abstract": "Bortezomib (V), lenalidomide (R), cyclophosphamide (C), and dexamethasone (D) are components of the most commonly used modern doublet (RD, VD) or triplet (VRD, CVD) initial induction regimens before autologous hematopoietic cell transplantation (AHCT) for multiple myeloma (MM) in the United States. In this study we evaluated 693 patients receiving \"upfront\" AHCT after initial induction therapy with modern doublet or triplet regimens using data reported to the Center for International Blood and Marrow Transplant Research from 2008 to 2013. Analysis was limited to those receiving a single AHCT after 1 line of induction therapy within 12 months from treatment initiation for MM. In multivariate analysis, progression-free survival (PFS) and overall survival were similar irrespective of induction regimen. However, high-risk cytogenetics and nonreceipt of post-transplant maintenance/consolidation therapy were associated with higher risk of relapse. Patients receiving post-transplant therapy had significantly improved 3-year PFS versus no post-transplant therapy (55% versus 39%, P = .0001). This benefit was most evident in patients not achieving at least a complete response post-AHCT (P = .005). In patients receiving upfront AHCT, the choice of induction regimen (doublet or triplet therapies) appears to be of lower impact than use of post-transplant therapy.", "doi": "10.1016/j.bbmt.2016.11.011", "pmid": "27864161", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS841774"}, {"db": "pmc", "key": "PMC5346183"}, {"db": "pii", "key": "S1083-8791(16)30489-X"}], "notes": [], "created": "2026-09-23T11:46:05.616Z", "modified": "2026-09-23T11:46:05.641Z"}, {"entity": "publication", "iuid": "d387b089bdf742bfaa1fb3d1f8a03465", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/d387b089bdf742bfaa1fb3d1f8a03465.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/d387b089bdf742bfaa1fb3d1f8a03465"}}, "title": "Allogeneic Transplantation for Relapsed Waldenstr\u00f6m Macroglobulinemia and Lymphoplasmacytic Lymphoma.", "authors": [{"family": "Cornell", "given": "Robert F", "initials": "RF"}, {"family": "Bachanova", "given": "Veronika", "initials": "V"}, {"family": "D'Souza", "given": "Anita", "initials": "A"}, {"family": "Woo-Ahn", "given": "Kwang", "initials": "K"}, {"family": "Martens", "given": "Michael", "initials": "M"}, {"family": "Huang", "given": "Jiaxing", "initials": "J"}, {"family": "Al-Homsi", "given": "A Samer", "initials": "AS"}, {"family": "Chhabra", "given": "Saurabh", "initials": "S"}, {"family": "Copelan", "given": "Edward", "initials": "E"}, {"family": "Diaz", "given": "Miguel-Angel", "initials": "MA"}, {"family": "Freytes", "given": "Cesar O", "initials": "CO"}, {"family": "Gale", "given": "Robert Peter", "initials": "RP"}, {"family": "Ganguly", "given": "Siddhartha", "initials": "S"}, {"family": "Hamadani", "given": "Mehdi", "initials": "M"}, {"family": "Hildebrandt", "given": "Gerhard", "initials": "G"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Kharfan-Dabaja", "given": "Mohamed", "initials": "M"}, {"family": "Kindwall-Keller", "given": "Tamila", "initials": "T"}, {"family": "Lazarus", "given": "Hillard M", "initials": "HM"}, {"family": "Marks", "given": "David I", "initials": "DI"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Olsson", "given": "Richard F", "initials": "RF"}, {"family": "Saad", "given": "Ayman", "initials": "A"}, {"family": "Usmani", "given": "Saad", "initials": "S"}, {"family": "Vesole", "given": "David H", "initials": "DH"}, {"family": "Yared", "given": "Jean", "initials": "J"}, {"family": "Mark", "given": "Tomer", "initials": "T"}, {"family": "Nieto", "given": "Yago", "initials": "Y"}, {"family": "Hari", "given": "Parameswaran", "initials": "P"}], "type": "journal article", "published": "2017-01-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "23", "issue": "1", "pages": "60-66", "issn-l": null}, "abstract": "Waldenstr\u00f6m macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is characterized by lymphoplasmacytic proliferation, lymph node and spleen enlargement, bone marrow involvement, and IgM production. Treatment varies based on the extent and biology of disease. In some patients, the use of allogeneic hematopoietic cell transplantation (alloHCT) may have curative potential. We evaluated long-term outcomes of 144 patients who received adult alloHCT for WM/LPL. Data were obtained from the Center for International Blood and Marrow Transplant Research database (2001 to 2013). Patients received myeloablative(n = 67) or reduced-intensity conditioning (RIC; n = 67). Median age at alloHCT was 53 years, and median time from diagnosis to transplantation was 41 months. Thirteen percent (n = 18) failed prior autologous HCT. About half (n = 82, 57%) had chemosensitive disease at the time of transplantation, whereas 22% had progressive disease. Rates of progression-free survival, overall survival, relapse, and nonrelapse mortality at 5 years were 46%, 52%, 24%, and 30%, respectively. Patients with chemosensitive disease and better pretransplant disease status experienced significantly superior overall survival. There were no significant differences in progression-free survival based on conditioning (myeloablative, 50%, versus RIC, 41%) or graft source. Conditioning intensity did not impact treatment-related mortality or relapse. The most common causes of death were primary disease and graft-versus-host disease (GVHD). AlloHCT yielded durable survival in select patients with WM/LPL. Strategies to reduce mortality from GVHD and post-transplant relapse are necessary to improve this approach.", "doi": "10.1016/j.bbmt.2016.10.010", "pmid": "27789362", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS825027"}, {"db": "pmc", "key": "PMC5182098"}, {"db": "pii", "key": "S1083-8791(16)30424-4"}], "notes": [], "created": "2026-09-23T11:51:26.017Z", "modified": "2026-09-23T11:51:26.047Z"}, {"entity": "publication", "iuid": "52bd0bb2b07d4e38b259831573870c38", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/52bd0bb2b07d4e38b259831573870c38.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/52bd0bb2b07d4e38b259831573870c38"}}, "title": "Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.", "authors": [{"family": "Chaudhury", "given": "Sonali", "initials": "S"}, {"family": "Sparapani", "given": "Rodney", "initials": "R"}, {"family": "Hu", "given": "Zhen-Huan", "initials": "ZH"}, {"family": "Nishihori", "given": "Taiga", "initials": "T"}, {"family": "Abdel-Azim", "given": "Hisham", "initials": "H"}, {"family": "Malone", "given": "Adriana", "initials": "A"}, {"family": "Olsson", "given": "Richard", "initials": "R"}, {"family": "Hamadani", "given": "Mehdi", "initials": "M"}, {"family": "Daly", "given": "Andrew", "initials": "A"}, {"family": "Bacher", "given": "Ulrike", "initials": "U"}, {"family": "Wirk", "given": "Baldeep M", "initials": "BM"}, {"family": "Kamble", "given": "Rammurti T", "initials": "RT"}, {"family": "Gale", "given": "Robert P", "initials": "RP"}, {"family": "Wood", "given": "William A", "initials": "WA"}, {"family": "Hale", "given": "Gregory", "initials": "G"}, {"family": "Wiernik", "given": "Peter H", "initials": "PH"}, {"family": "Hashmi", "given": "Shahrukh K", "initials": "SK"}, {"family": "Marks", "given": "David", "initials": "D"}, {"family": "Ustun", "given": "Celalettin", "initials": "C"}, {"family": "Munker", "given": "Reinhold", "initials": "R"}, {"family": "Savani", "given": "Bipin N", "initials": "BN"}, {"family": "Alyea", "given": "Edwin", "initials": "E"}, {"family": "Popat", "given": "Uday", "initials": "U"}, {"family": "Sobecks", "given": "Ronald", "initials": "R"}, {"family": "Kalaycio", "given": "Matt", "initials": "M"}, {"family": "Maziarz", "given": "Richard", "initials": "R"}, {"family": "Hijiya", "given": "Nobuko", "initials": "N"}, {"family": "Saber", "given": "Wael", "initials": "W"}], "type": "journal article", "published": "2016-06-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "22", "issue": "6", "pages": "1056-1064", "issn-l": null}, "abstract": "Chronic myeloid leukemia (CML) in children and young adults is uncommon. Young patients have long life expectancies and low morbidity with hematopoietic cell transplantation (HCT). Prolonged tyrosine kinase inhibitor (TKI) use may cause significant morbidity. In addition, indication for HCT in patients in the first chronic phase is not established. We hence retrospectively evaluated outcomes in 449 CML patients with early disease receiving myeloablative HCT reported to the CIBMTR. We analyzed various factors affecting outcome, specifically the effect of age and pre-HCT TKI in pediatric patients (age < 18 years, n = 177) and young adults (age 18 to 29 years, n = 272) with the goal of identifying prognostic factors. Post-HCT probability rates of 5-year overall survival (OS) and leukemia-free survival (LFS) were 75% and 59%, respectively. Rates of OS and LFS were 76% and 57% in <18-year and 74% and 60% in 18- to 29-year group, respectively, by univariate analysis (P = .1 and = .6). Five-year rates of OS for HLA matched sibling donor (MSD) and bone marrow (BM) stem cell source were 83% and 80%, respectively. In multivariate analysis there was no effect of age (<18 versus 18 to 29) or pre-HCT TKI therapy on OS, LFS, transplant related mortality, or relapse. Favorable factors for OS were MSD (P < .001) and recent HCT (2003 to 2010; P = .04). LFS was superior with MSD (P < .001), BM as graft source (P = .001), and performance scores > 90 (P = .03) compared with unrelated or mismatched peripheral blood stem cells donors and recipients with lower performance scores. Older age was associated with increased incidence of chronic graft-versus-host disease (P = .0002). In the current era, HCT outcomes are similar in young patients and children with early CML, and best outcomes are achieved with BM grafts and MSD.", "doi": "10.1016/j.bbmt.2016.02.015", "pmid": "26964698", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS777769"}, {"db": "pmc", "key": "PMC4877686"}, {"db": "pii", "key": "S1083-8791(16)00120-8"}], "notes": [], "created": "2026-09-23T09:51:22.545Z", "modified": "2026-09-23T10:25:23.248Z"}], "created": "2026-09-23T07:29:49.641Z", "modified": "2026-09-23T07:29:49.641Z"}